𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

✍ Scribed by Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras CW Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson

Book ID
117287055
Publisher
The Lancet
Year
2004
Tongue
English
Weight
216 KB
Volume
364
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Expression of Bcl-2 in gastrointestinal
Expression of Bcl-2 in gastrointestinal stromal tumors : Correlation with progression-free survival in 81 patients treated with imatinib mesylate
✍ Dejka M. Steinert; Mauricio Oyarzo; Xuemei Wang; Haesun Choi; Peter F. Thall; L. πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 224 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The natural history of gastrointestinal stromal tumor (GIST) has been revolutionized by imatinib mesylate (imatinib) therapy. Before imatinib, Bcl‐2 expression in GIST was associated with a worse prognosis or added no additional prognostic value. To the authors' knowledge